γδT Cell Infusion to Prevent Relapsed/Refractory Leukemia Rescue Relapse

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

EARLY_PHASE1

Total Enrollment

5 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-05-01

Study Completion Date

2021-05-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Safety and Effectiveness of Donor γδT Cell Infusion to Prevent Relapsed/Refractory Leukemia Rescue Relapse After Allogeneic Hematopoietic Stem Cell Transplantation

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Donor Dendritic Cells And Donor Lymphocytes in Patients With Relapsed Hematologic Malignancies After Allogeneic Transplant

NCT00476177

Hematologic Malignancy

COMPLETED PHASE1

Safety and Efficiency of γδ T Cell Against Hematological Malignancies After Allo-HSCT

NCT04764513

Acute Myeloid Leukemia Acute Lymphoblastic Leukemia Myelodysplastic Syndromes +1 more

UNKNOWN PHASE1/PHASE2

Donor Lymphocyte Infusion After Alternative Donor Transplantation

NCT01027702

Immunodeficiency

TERMINATED PHASE1/PHASE2

IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation

NCT04628338

Myelodysplastic Syndromes Myeloid Leukemia Allogeneic Stem Cell Transplantation

COMPLETED EARLY_PHASE1

Donor Lymphocyte Infusion (DLI) for Relapsed (Post Transplant) Leukemia

NCT00167167

Leukemia, Myeloid, Chronic AML MDS +1 more

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

γδT cells belong to the innate immune system and have a powerful anti-tumor effect. Leukemia patients transplanted with allogeneic hematopoietic stem cells have an important role in controlling leukemia recurrence. Although adoptive immunotherapy using in vitro expanded γδT cells has achieved significant results in patients with solid tumors, infusion of donor γδT cells in leukemia patients undergoing allogeneic hematopoietic stem cell transplantation to prevent leukemia recurrence has not been reported. . This clinical study intends to initially observe the safety and effectiveness of donor γδT cell infusion to prevent recurrence/refractory leukemia salvage allogeneic hematopoietic stem cell transplantation to further improve the transplantation effect of these patients

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Leukemia, B-cell

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

γδT

γδT,Infusion,iv,0.5×10\^6-8×10\^7γδT /kg,once.

Group Type EXPERIMENTAL

γδT Cell infusion agent

Intervention Type DRUG

γδT

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

γδT Cell infusion agent

γδT

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Acute leukemia patients undergoing salvage allogeneic hematopoietic stem cell transplantation
* Age 10-65,Any gender
* Expected lifetime\>3months
* ECOG 0-2
* DSA Negative
* Successful granulocyte implantation
* Liver and kidney function, heart and lung function meet the following requirements:①Creatinine≤1.5 ULN；②ALT/AST ≤5 ULN； ③Baseline oxygen saturation≥92%； ④Left ventricular ejection fraction≥50%
* Female subjects with fertility who had a negative pregnancy test within 48 hours before the infusion and were not breastfeeding; all subjects with fertility potential before enrolling in the study and throughout the study period until the last infusion Within 3 months, take adequate contraceptive measures
* Signing informed consent patients must be able to understand and be willing to participate in this study, and sign informed consent at the same time

Exclusion Criteria

* Donor HBsAg or HBcAb positive and HBV DNA titer test is not within the normal reference value; donor or patient HCV antibody positive and peripheral blood HCV RNA positive; donor or patient HIV antibody positive; donor syphilis test positive
* Active central nervous system disease
* BMI index\>35
* Allergic to DMSO
* Graft-versus-host disease
* Septic shock
* Systemic steroid therapy is required during cell infusion or cell collection, or there are conditions that researchers believe may require steroid therapy during blood collection or during infusion. In addition to cell collection or infusion, steroids for disease treatment are allowed, and inhaled steroids or hydrocortisone are also allowed for physiological replacement therapy in patients with adrenal insufficiency
* Participated in another clinical trial within 4 weeks before enrolling in the study, or intend to participate in another clinical trial throughout the study
* According to the judgment of the investigator, it does not meet the situation of cell preparation
* Circumstances considered by other researchers to be inappropriate

Minimum Eligible Age

10 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No